If you enjoyed the US edition of the CRISPR patent dispute, get ready for the European one: With the announcement last week that the European Patent Office intends to grant a patent to the University of California, Berkeley, and its partners covering a broad range of uses of the revolutionary genome-editing technology, expect a similar plot to unfold on that side of the Atlantic.

In particular, “now we go through opposition proceedings in Europe, where 3d parties can challenge the patent,” patent expert Jacob Sherkow of New York Law School tweeted. “And that could take a while.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Please help me i have server ulcer colitis crispr could be my cure to a normal life again please contact me @904 480 8891

  • Isn’t CRISPR-Cas9 gene editing set to be overtaken shortly by peptide nucleic acid (PNA) gene editing anyway making these legal fights somewhat pointless?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy